Scientific-stage biopharmaceutical firm Immatics N.V. (NASDAQ:IMTX) priced its beforehand introduced underwritten public providing of 16.25M shares at a public providing worth of $9.25 per share.
The gross proceeds from the providing are anticipated to be roughly $150M.
The providing is anticipated to shut on October 15, 2024.
Underwriters have a 30-day choice to buy as much as ~2.44M further shares.
The gross proceeds from the providing are anticipated to be roughly $150M.
The providing is anticipated to shut on October 15, 2024.
Underwriters have a 30-day choice to buy as much as ~2.44M further shares.
